Shanta Shepherd, MD
Urology · Hartford, CTNPI 1174986756
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,416 of the $8,394 with a category attached, or 76.4%. 31 manufacturers reported payments, led by Coloplast at 32.9% of the total. Reporting peaked in 2024 at $2,592 and has fallen 73.3% since, to $691 in 2025.
Across 258 payments — averaging $32.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$3K
- Axonics, Inc.$1K
- Sumitomo Pharma America, Inc.$724
- Teleflex LLC$473
- Endo Pharmaceuticals Inc.$460
- Merck$386
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1,97724%
- Food & beverage$6,41676%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 33 | $2,765 |
| Axonics, Inc. | 27 | $1,185 |
| Sumitomo Pharma America, Inc. | 38 | $724 |
| Teleflex LLC | 9 | $473 |
| Endo Pharmaceuticals Inc. | 29 | $460 |
| Merck | 17 | $386 |
| Bayer | 9 | $283 |
| Tolmar, Inc. | 7 | $200 |
| Urovant Sciences Inc | 13 | $193 |
| Accord Healthcare, Inc. | 9 | $190 |
| Myriad Genetic Laboratories, Inc. | 9 | $143 |
| Astellas Pharma US Inc | 7 | $140 |
| AbbVie | 6 | $136 |
| Johnson & Johnson | 5 | $114 |
| Innovation Technologies Inc | 1 | $114 |
| Medtronic | 4 | $102 |
| Myovant Sciences Inc. | 4 | $93 |
| Agiliti Surgical, Inc. | 4 | $80 |
| Boston Scientific | 3 | $79 |
| Progenics Pharmaceuticals, Inc. | 4 | $78 |
| Antares Pharma, Inc. | 3 | $78 |
| Pfizer | 4 | $75 |
| Calyxo, Inc. | 2 | $61 |
| Endo USA, Inc. | 2 | $54 |
| Ferring Pharmaceuticals Inc. | 2 | $44 |
| Mission Pharmacal Company | 2 | $43 |
| Halozyme Inc | 1 | $25 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23 |
| Olympus America Inc. | 1 | $19 |
| Urogen Pharma, Inc. | 1 | $19 |
| Immunitybio, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,394 in reported general payments places this provider in the 80th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 37 | $554,966 |
| MyrbetriqMirabegron | 168 | $163,452 |
| GemtesaVibegron | 126 | $133,826 |
| OrgovyxRelugolix | 19 | $52,350 |
| Mirabegron ErMirabegron | 22 | $14,707 |
| Tamsulosin Hcl | 461 | $6,202 |
| Estradiol | 95 | $4,802 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 44 | $4,446 |
| Methenamine Hippurate | 57 | $3,869 |
| Trospium Chloride | 47 | $2,230 |
| Finasteride | 188 | $2,104 |
| Trospium Chloride ErTrospium Chloride | 12 | $1,140 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,003 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 39 | $937 |
| Solifenacin Succinate | 19 | $840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $114 | $554,96637 claims |
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $724 | $186,176145 claims |
| Astellas Pharma US IncMyrbetriq | $140 | $163,452168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 urology providers in Connecticut.
Other urology in Hartford
- Steven ShichmanHartford$28K
- Joseph WagnerHartford$21K
- Eric KatzHartford$14K
- Jared BieniekHartford$9K
- Christine CumarasamyHartford$6K
- Guy TronoHartford$6K
- Abram DamatoHartford$6K
- Peter BoscoHartford$3K
- Aaron TurnquistHartford$3K
- Daniel KellnerNew Haven$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.